<DOC>
	<DOC>NCT00534599</DOC>
	<brief_summary>This study is being carried out to see if extended release quetiapine fumarate (SeroquelÂ®XL) when added to standard selective serotonin reuptake inhibitor (SSRI) / serotonin-norepinephrine reuptake inhibitor (SNRI) therapy is effective and safe for the treatment of Generalized Anxiety Disorder in patients with partial or no response to SSRI/SNRI alone or in combination with a benzodiazepine, and if so, how it compares with placebo</brief_summary>
	<brief_title>Generalized Anxiety Disorder Adjunct Study</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Provision of Informed Consent Documented diagnosis of Generalized Anxiety Disorder Female patients must not be pregnant and be willing to use a reliable method of birth control Be able to understand and comply with study requirements Other psychiatric disorders that could confound the study results, as judged by the study doctor Moderate to severe depression Other clinically relevant diseases, as judged by the study doctor Medication that you are taking, as judged by the study doctor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Generalized anxiety disorders</keyword>
	<keyword>anxiety</keyword>
	<keyword>adjunct treatment in anxiety</keyword>
	<keyword>anxiety disorder</keyword>
	<keyword>partial or non-responder in anxiety</keyword>
</DOC>